91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
91黑料 CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
-
, Senior VP, Patient, Site & Decentralised Solutions, on why the future of drug development involves decentralising parts of the clinical trial process.
-
(pages 16-17) features a thought leadership piece by Rose Kidd which examines the benefits of agile clinical monitoring in study management.
-
91黑料 talks about the inclusivity of decentralised trials
Patients as Partners Autumn newsletter (pages 14 & 15) features a Q&A with EB McLindon, Senior VP, Site, Patient and Decentralised Solutions, on the inclusivity of decentralised clinical trials.
-
With in-person scientific congresses an impossibility for the foreseeable future, researchers and publishers have to adapt how they foster scientific exchange.
-
that examines how innovation, from the development of targeted therapies to a revolution in clinical trial designs, puts an emphasis on patient centricity.
-
In a wide-ranging interview with , 91黑料 CIO, Tom O’Leary highlights the role of and the steps that still need to be taken to better match .
-
91黑料's CIO Tom O'Leary provides expert commentary on in this January 2020 Bio IT World Article.
